Carlos Victor Montefusco Pereira, PhD, Freelance Consultant, Researcher in Clinical Trial Analytics at Hasso Plattner Institute, ex BioNTech, ex Boehringer Ingelheim
Carlos Victor Montefusco Pereira, PhD, Freelance Consultant, Researcher in Clinical Trial Analytics at Hasso Plattner Institute, ex BioNTech, ex Boehringer Ingelheim
Carlos Victor Montefusco Pereira, PhD, Freelance Consultant, Researcher in Clinical Trial Analytics at Hasso Plattner Institute, ex BioNTech, ex Boehringer Ingelheim
Biography
I am a Brazilian Manauara scientist working across clinical trials, nanomedicine, and data science. My path moved from pharmacology and toxicology into pharmaceutical development, and then into global clinical trials involving biologics, mRNA, CAR-T, and nanoparticle-based therapies.
During my PhD in Germany, I developed advanced human lung models to better understand how drugs behave in biologically realistic systems. In industry, I worked on in-use stability of biologics and later across mRNA platforms, clinical operations, pharmacometrics, and immunogenicity strategy in global trials.
Today, my work focuses on something that connects all of these experiences. Making sure that what we design, what we measure, and what patients actually experience are part of the same system.
Interview
NanoSphere: Tell us a bit about yourself—your background, journey, and what led you to where you are today.
Carlos: I come from Manaus, in the Brazilian Amazon, and for me that has always been a source of perspective, not limitation. It is one of the most biologically diverse places in the world, and growing up in that environment shapes how you think. You learn early that biology is dynamic, interconnected, and highly dependent on context.
When I moved into pharmaceutical science, I carried that way of thinking with me. I was naturally drawn to systems rather than isolated components. During my PhD, I developed a 3D lung infection model, and what stood out was that the more realistic the system became, the more nuanced and less predictable the drug response was. It was not discouraging. It was clarifying. It showed where deeper understanding was needed.
Later, in industry, working with biologics, mRNA, and cell therapies, I saw that complexity again, this time in clinical reality. The product defined during development interacts with handling, workflows, and patient variability in ways that are not always fully captured. For me, that is not a problem to avoid. It is where the real opportunity is. It is where better science, better integration, and better decisions can make a difference.
NanoSphere: As part of the mRNAVAC Working Party, how do you think about setting quality standards for mRNA vaccines that are robust enough to protect patients, yet flexible enough to accommodate rapid platform evolution and global manufacturing diversity?
Carlos: Working with mRNA in clinical trials gives you a very practical view of quality. These are not static products. They are evolving platforms, and that makes them powerful but also demanding in how we define and maintain standards.
What becomes clear is that quality is not only about defining attributes in controlled settings. It is about ensuring that those attributes remain meaningful across development, manufacturing, and clinical use. That requires a balance between robustness and flexibility.
From my experience, one of the most important areas for progress is alignment. Alignment in how measurements are generated, how they are interpreted, and how they relate to clinical outcomes. Many groups are already producing high-quality data, but the real value comes when that data can be compared, connected, and understood across contexts.
This is where I see a very positive direction for the field. As platforms mature, there is a growing opportunity to build shared frameworks that support both innovation and consistency. If we can strengthen that alignment, we can make mRNA not only fast-moving, but also scalable and reliable at a global level.
NanoSphere: What breaks down first when CMC, clinical, and data teams stop speaking the same language—and how do you personally intervene when that happens?
Carlos: In complex therapies, the biggest challenges often come from misalignment rather than lack of expertise. Different teams look at the same system from different angles, and each perspective is valid. The difficulty arises when those perspectives are not fully connected.
For example, a product may be well characterized from a CMC perspective, while clinical teams adapt workflows to real-world conditions, and modeling teams build assumptions based on structured data. Each layer adds value, but they need to describe the same reality to be truly effective.
In areas like immunogenicity or advanced delivery systems, small differences in how data is generated or interpreted can lead to very different conclusions. Recognizing this early and bringing those perspectives together is where a lot of value can be created.
This is also where data science can play a very constructive role. Not as a replacement for expertise, but as a way to structure information, make assumptions visible, and support shared understanding. When teams align around a clear representation of the system, decisions become more robust and more transparent.
NanoSphere: If there’s one key message or insight you’d like to share with readers about the future of nanomedicine, what would it be?
Carlos: As a Manauara scientist, I do not see nanomedicine as a luxury technology. I see it as a test of whether advanced science can become globally useful, clinically interpretable, and accessible beyond the usual centers of innovation.
Carlos's references
- My GitHub, which includes selected projects connecting clinical trials, immunogenicity, and applied data science:
https://github.com/camontefusco - Selected projects:
- ADA-Immunogenicity-ClinPharm-CDISC-FHIR-Interoperability-Framework
This project focuses on translating anti-drug antibody (ADA) data into standardized clinical pharmacology datasets and interoperable formats such as CDISC and FHIR, supporting immunogenicity-driven decision making and regulatory submissions. - RWE-AWS-Integration-Interoperability-Pipeline
An end-to-end pipeline integrating real-world evidence data into structured models and interoperable formats, demonstrating how clinical data can move from ingestion to analysis and reporting in a scalable and regulatory-aligned way. - Streamlit App for mRNA BioPharma Data Exploration
An interactive application designed for non-technical users to explore clinical, operational, and safety data related to mRNA-based therapies, bridging the gap between complex datasets and practical usability.
- ADA-Immunogenicity-ClinPharm-CDISC-FHIR-Interoperability-Framework
- My ORCID profile for a full overview of my scientific publications:
https://orcid.org/0000-0003-4167-4653 - A representative publication that reflects my work connecting pharmaceutical development and clinical reality: Montefusco Pereira CV et al., Drug Discovery Today (2023). “Steps toward nebulization in-use studies to understand the stability of new biological entities.” https://doi.org/10.1016/j.drudis.2022.103461